Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03394209
Recruitment Status : Completed
First Posted : January 9, 2018
Last Update Posted : May 15, 2019
Sponsor:
Collaborators:
Beijing Institute of Pharmacology and Toxicology
University of Oxford
Centers for Disease Control and Prevention, China
Information provided by (Responsible Party):
Bin Cao, China-Japan Friendship Hospital

Brief Summary:

Title: An adaptive study of the pharmacokinetics of favipiravir in patients with severe influenza Study Design: An open label, single group assignment, adaptive study to evaluate the pharmacokinetics of favipiravir in adult patients with severe influenza.

In the first stage, participants will receive favipiravir 1600mg BID on day 1, followed by favipiravir 600mg BID for 9 days.

If the proportion of patients with a minimum observed plasma trough concentration above the MEC (20μg/ml) at all measured time points after the second dose is less than 80% then a second patient cohort will be recruited and will receive favipiravir 1800mg BID on day 1, followed by favipiravir 800mg BID for 9 days.

Intervention: The 1st stage: 1600mg BID on day 1, followed with 600mg BID for 9 days. Sample size: 15 The 2nd stage: 1800mg BID on day 1, followed with 800mg BID for 9 days. Sample size: 15 Population: Males and females aged 18 years or older admitted to hospital with a positive PCR test for influenza and a PaO2/FiO2≤300mmHg or/and on mechanical ventilation for severe lung infection on admission.

Sample size 15 or 30 severe influenza patients Research hypothesis The administration of oral favipiravir at either 1600mg/600mg BID or 1800/800mg BID will result in ≥ 80% patients achieving a minimum observed plasma trough concentration above the MEC (20μg/ml) at all measured time points after the second dose.

Phase: Phase 2a, PK, safety and feasibility study. Description of Study Agent: Favipiravir (T-705) a viral RNA-dependent RNA polymerase inhibitor.

Study Duration: 1 year Participant Duration: 38 days


Condition or disease Intervention/treatment Phase
Influenza, Human Critical Illness Influenza Drug: Favipiravir Drug: Oseltamivir 75Mg Capsule Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

This is a adaptive study, which include two steps.

1st step: 1600mg BID on day 1, followed by 600mg BID for 9 days. Sample size: 15 PK analysis: If the proportion of patients with a minimum observed plasma trough concentration above the MEC (20μg/ml) at all measured time points after the second dose is greater than or equal to 80% then the dose is considered adequate and the study will be completed. If not, then a second patient cohort will be recruited and will receive favipiravir 1800mg BID on day 1, followed by favipiravir 800mg BID for 9 days. Sample size: 15

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe
Actual Study Start Date : February 6, 2018
Actual Primary Completion Date : February 20, 2019
Actual Study Completion Date : March 27, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
Drug Information available for: Oseltamivir

Arm Intervention/treatment
Experimental: Favipiravir+oseltamivir
Favipiravir+oseltamivir will be given twice daily for a 10-day period.
Drug: Favipiravir

In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.

In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily.

Other Name: T-705

Drug: Oseltamivir 75Mg Capsule
oseltamivir will be administered at 75mg twice daily orally for 10 days




Primary Outcome Measures :
  1. Proportion of patients with minimum plasma of Favipiravir trough concentration above the MEC (20μg/ml) at all measured time points after the second dose. [ Time Frame: 10 days during the intervention period ]

Secondary Outcome Measures :
  1. Maximum plasma concentration observed over the treatment period (Cmax ) [ Time Frame: 10 days during the intervention period ]
  2. Minimum plasma concentration observed over the treatment period (Cmin) [ Time Frame: 10 days during the intervention period ]
  3. Average pre-dose plasma concentration (Trough) [ Time Frame: 10 days during the intervention period ]
  4. Proportion of patients whose favipiravir plasma concentration at least one time exceeds MEC in study days [ Time Frame: 10 days during the intervention period ]
  5. The proportion of patients falling into each category of a five-point ordinal scale on day 10 and day 28 after starting favipiravir [ Time Frame: 28 days from starting intervention ]
    The category of a five-point ordinal scale: death; hospitalised on ECMO and/or mechanical ventilation; hospitalised on supplemental oxygenation; hospitalised not on supplemental oxygenation; discharged.

  6. Duration (days) of mechanical ventilation [ Time Frame: from reception of mechanical ventilation to ventilator weening, an average of 10 days ]
  7. Duration (days) of extracorporeal membrane oxygenation [ Time Frame: from starting ECMO to weening, an average of 9 days ]
  8. Duration (days) of supplemental oxygenation [ Time Frame: Duration (days) of hospitalization with oxygen therapy,an average of 13 days ]
  9. Duration (days) of hospitalization [ Time Frame: Days from admission to discharge,an average of 19 days ]
  10. The proportion of patients with a negative RT-PCR for influenza from upper and/or lower respiratory tract samples on day 10 after starting treatment [ Time Frame: Duration of viral shedding,an average of 15 days ]
  11. The time (days) to negative RT-PCR for influenza from upper and/or lower respiratory tract samples (capped at day 10) [ Time Frame: Duration of viral shedding,an average of 15 days ]
  12. The proportion of patients with drug related adverse events [ Time Frame: 38 days from starting intervention ]
  13. The proportion of patients with genetic and phenotypic markers of resistance to favipiravir and/or oseltamivir [ Time Frame: Days from admission to discharge,an average of 19 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Hospitalized males or females with a positive PCR test for influenza virus infection
  2. Adults aged ≥18years
  3. PaO2/FiO2≤300mmHg or on mechanical ventilation
  4. < 10 days since symptom onset
  5. Negative pregnancy testing for childbearing age females (under 60 years)
  6. Willingness to use contraception for 7 days after end of treatment
  7. Informed consent
  8. In addition, male subjects must:

    1. Agree not to donate sperm during the study and for 7 days following the last dose of study drug, and
    2. Agree to adhere strictly to one of the following contraceptive measures from the Screening Visit until 7 days after the last dose of study drug:

    i. abstain from sexual intercourse or ii. have a female partner using effective means of birth control as noted below or iii. use a condom with spermicide or a second barrier method by female partner.

Female subjects

a. Of child-bearing potential must agree to adhere strictly to one of the following approved contraceptive measures during the study and for 7 days after the last dose of study drug: i. abstain from sexual intercourse or ii. have a male partner incapable of fathering a child (eg, had a vasectomy at least 6 months with history of negative semen analysis prior Screening or iii. use of one of the following methods, in combination with condom and spermicide use by a male partner: nonhormonal intrauterine device (IUD); diaphragm; or hormonal contraceptives including oral contraceptives, injectable subdermal implants, hormonal IUD, or vaginal ring b. Be unable to bear children defined as one of the following: i. absence of a menstrual period for ≥12 consecutive months with FSH confirmation, ii. be 60 years of age or greater, iii. had surgical removal of uterus or removal of both ovaries, or iv. had undergone tubal ligation >6 weeks prior to Day 1 dosing

Exclusion Criteria:

  1. Any condition that does not allow for safely following the protocol
  2. Patient refusal to accept invasive organ support treatment if needed
  3. Pregnant or breastfeeding
  4. Any condition resulted to reception of renal replacement therapy
  5. AST > 5 times upper of limit or Child Pugh score ≥ C
  6. Serum uric acid level > 3 times upper level of normal (430 ummol/L) associated with symptoms of gout
  7. Has a history of gout or is under treatment for: gout or hyperuricemia; hereditary xanthinuria; hypouricemia or xanthine calculi of the urinary tract
  8. Has a history of hypersensitivity to an anti-viral nucleoside-analog drug targeting a viral RNA polymerase
  9. Physician makes a decision that trial involvement is not in patients' best interest.
  10. Currently or have been involved in another anti-influenza treatment trial in the last 28 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03394209


Locations
Layout table for location information
China
China-Japan Friendship Hospital
Beijing, China, 100029
Sponsors and Collaborators
Capital Medical University
Beijing Institute of Pharmacology and Toxicology
University of Oxford
Centers for Disease Control and Prevention, China
Additional Information:
Publications of Results:

Layout table for additonal information
Responsible Party: Bin Cao, Dr.Bin Cao, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier: NCT03394209    
Other Study ID Numbers: FAVI-PK-2017001
First Posted: January 9, 2018    Key Record Dates
Last Update Posted: May 15, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bin Cao, China-Japan Friendship Hospital:
Favipiravir, Influenza, Human, Critical Illness, Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Critical Illness
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Oseltamivir
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action